Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Greil

Showing results (311-320 of 483) with videos related to

Pageof 49
Sort By:
Journal of Hematology & Oncology|May 1, 2013
Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study GroupLisa Pleyer, Reinhard Stauder, Sonja Burgstaller, et al.
Blood Advances|August 12, 2025
Sustained Survival Benefit of Emicizumab and Postponed Immunosuppression in Acquired Hemophilia AInga M Schimansky, Christiane Dobbelstein, Robert Klamroth, et al.
Breast Cancer Research : BCR|February 2, 2019
Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR)Simon Peter Gampenrieder, Andreas Peer, Christian Weismann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2016
Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social ReintegrationKarolin Behringer, Helen Goergen, Horst Müller, et al.
Wiener Klinische Wochenschrift|February 1, 2018
Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemiaFlorian Huemer, Lukas Weiss, Viktoria Faber, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2020
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trialPeter C Dubsky, Christian F Singer, Daniel Egle, et al.
Breast Cancer Research : BCR|December 15, 2021
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-RegistrySimon Peter Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon, et al.
Breast (Edinburgh, Scotland)|February 17, 2020
Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUTGuenther G Steger, Daniel Egle, Rupert Bartsch, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 7, 2013
Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1Ellen Heitzer, Monika Artl, Martin Filipits, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2012
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neckFelix Keil, Edgar Selzer, Andrea Berghold, et al.
Pageof 49

Showing results (311-320 of 483) with videos related to

Sort By:
Pageof 49
Journal of Hematology & Oncology|May 1, 2013
Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study GroupLisa Pleyer, Reinhard Stauder, Sonja Burgstaller, et al.
Blood Advances|August 12, 2025
Sustained Survival Benefit of Emicizumab and Postponed Immunosuppression in Acquired Hemophilia AInga M Schimansky, Christiane Dobbelstein, Robert Klamroth, et al.
Breast Cancer Research : BCR|February 2, 2019
Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR)Simon Peter Gampenrieder, Andreas Peer, Christian Weismann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2016
Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social ReintegrationKarolin Behringer, Helen Goergen, Horst Müller, et al.
Wiener Klinische Wochenschrift|February 1, 2018
Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemiaFlorian Huemer, Lukas Weiss, Viktoria Faber, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2020
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trialPeter C Dubsky, Christian F Singer, Daniel Egle, et al.
Breast Cancer Research : BCR|December 15, 2021
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-RegistrySimon Peter Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon, et al.
Breast (Edinburgh, Scotland)|February 17, 2020
Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUTGuenther G Steger, Daniel Egle, Rupert Bartsch, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 7, 2013
Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1Ellen Heitzer, Monika Artl, Martin Filipits, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2012
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neckFelix Keil, Edgar Selzer, Andrea Berghold, et al.
Pageof 49